Next Article in Journal
Relevance of Serum Levels of Interleukin-6 and Syndecan-1 in Patients with Hepatocellular Carcinoma
Previous Article in Journal
Stability-Indicating RP-HPLC Method for the Simultaneous Estimation of Doxofylline and Terbutalinesulphate in Pharmaceutical Formulations
Article Menu

Article Versions

Export Article

Open AccessArticle
Sci. Pharm. 2012, 80(1), 167-178; doi:10.3797/scipharm.1111-05

Pharmacokinetics and Excretion Studies on CDRI-85/92, an Antiulcer Proton Pump Inhibitor

Pharmacokinetics and Drug Metabolism, Central Drug Research Institute, Lucknow, India
Received: 6 November 2011 / Accepted: 12 December 2011 / Published: 12 December 2011
Download PDF [183 KB, uploaded 29 September 2016]

Abstract

CDRI 85/92 is an antiulcer pharmacophore and a proton pump inhibitor, which is in an advanced stage of preclinical trials. In view of its importance, pharmacokinetic and excretion were studied in Sprague Dawley rats after administering 20 mg/kg oral and intravenous doses. The compound was detectable in the serum samples as early as 5 min post-oral administration. The compound was eliminated slowly from serum with an elimination half-life of 2.1 h. Following the 20 mg/kg oral dose, maximum serum concentration (Cmax) was found to be 469.28 ± 45.52 ng/ml after 1.0 h. Based on AUC values, the absolute bioavailability of the CDRI 85/92 was 70.5% after oral administration. It was found to be excreted in urine (~15% of the dose) in intravenously treated (bile duct cannulated as well as noncannulated) rats, whereas bile and feces depicted insignificant levels of the compound.
Keywords: CDRI Compound 85/92; Antiulcer pharmacophore; Bioavailability; Pharmacokinetics; Excretion; PPI CDRI Compound 85/92; Antiulcer pharmacophore; Bioavailability; Pharmacokinetics; Excretion; PPI
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

SRIVASTAVA, P. Pharmacokinetics and Excretion Studies on CDRI-85/92, an Antiulcer Proton Pump Inhibitor. Sci. Pharm. 2012, 80, 167-178.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top